Clinical and Translational Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer
ConclusionsIn conclusion, this study highlights the importance of adherence to the guidelines and appropriate use of PET/CT in early-stage breast cancer management. PET/CT should be reserved for cases where it is clinically warranted, considering the potential economic burden and minimal impact on treatment decisions of breast cancer tumor board in this patient population. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 19, 2024 Category: Cancer & Oncology Source Type: research

Correction: Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first ‑line immunochemotherapy
(Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 19, 2024 Category: Cancer & Oncology Source Type: research

Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
ConclusionFor patients with advanced non-selective PD-L1 NSCLC, two effective regimens are Pen  + CT and Niv + Bev + CT, which rank first in OS and PFS among all patients. Cam + CT and Tor + CT have advantages for OS in patients with SqNSCLC and Non-sqNSCLC, respectively. Niv + Ipi + CT provided the best OS benefit for patients with an ECOG score of 0, while Pem  + CT may be the most effective treatment for patients with an ECOG score of 1. Pem + CT has a better effect on female patients and non-smokers. Sin + CT was found to be the most effective treatment for male patients and the ...
Source: Clinical and Translational Oncology - April 16, 2024 Category: Cancer & Oncology Source Type: research

An overview of current research on cancer stem cells: a bibliometric analysis
ConclusionThe research on CSCs has garnered growing interest. A trend toward multidisciplinary homogeneity is emerging within the realm of CSCs. Further investigation could potentially center on the patients of extracellular vesicles and the tumor microenvironment in relation to CSCs. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 16, 2024 Category: Cancer & Oncology Source Type: research

Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations
ConclusionNSCLC patients with MET alterations can benefit from immunotherapy, especially the patients treated by combined ICI therapy. However, special attention should be paid to the occurrence of grade 3/4 adverse reactions while using the combined ICI therapy. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 16, 2024 Category: Cancer & Oncology Source Type: research

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment
ConclusionIn the first-line treatment, combination regimen has advantages over single regimen. Among them, chemotherapy combined with immunotherapy plus antiangiogenic therapy can achieve significant efficacy benefits. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 16, 2024 Category: Cancer & Oncology Source Type: research

Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study
ConclusionPDAC is an aggressive malignancy with male gender and black race are associated with a poor prognosis. Surgery with chemoradiation was associated with the best overall survival. With steadily increasing rates of PDAC, improved treatment modalities are paramount to improving survival in these patients. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 14, 2024 Category: Cancer & Oncology Source Type: research

Prevalence and risk factors of thyroid nodules in breast cancer women with different clinicopathological characteristics: a cross-sectional study
ConclusionsPrevalence of TN, especially TI-RADS  ≥ 4 TN, in Chinese early-stage BC women was higher than healthy people. HR-positive patients had higher prevalence and risk of TN, while without difference between HR-negative patients and healthy people. The increased risk of TN was correlated with ER-positive, PR-positive, lower Ki-67 expre ssion, and smaller tumor size. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 12, 2024 Category: Cancer & Oncology Source Type: research

Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients ( ≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study
ConclusionThe study demonstrated that individuals older than 65  years with locally advanced or metastatic ESCC have a survival benefit from the first-line treatment of PD-1 inhibitors combined therapy, with a manageable safety profile. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 11, 2024 Category: Cancer & Oncology Source Type: research

Heterogeneity and interplay: the multifaceted role of cancer-associated fibroblasts in the tumor and therapeutic strategies
This article underscores the multifarious roles of CAFs within the tumor microenvironment and their potential applications in cancer treatment, highlighting their importance as key targets in overcoming drug resistance and enhancing the efficacy of tumor therapies. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 11, 2024 Category: Cancer & Oncology Source Type: research

Explainable and visualizable machine learning models to predict biochemical recurrence of prostate cancer
ConclusionsOur score system provide reference for the identification for BCR, and the crafting of a framework for making therapeutic decisions for PCa on a personalized basis. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 11, 2024 Category: Cancer & Oncology Source Type: research

Exploring research progress in studying serum exosomal miRNA-21 as a molecular diagnostic marker for breast cancer
AbstractBreast cancer is one of the most prevalent malignancies affecting women globally and poses a significant public health challenge. Early clinical detection plays a pivotal role in providing optimal treatment opportunities and favorable prognoses, crucial for reducing breast cancer mortality and enhancing patients ’ quality of life. Therefore, the timely identification and diagnosis of breast cancer are imperative. Conventional tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3), serve as reliable methods for actively monitoring disease progression and have become a routine ...
Source: Clinical and Translational Oncology - April 11, 2024 Category: Cancer & Oncology Source Type: research

ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer
DiscussionECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 10, 2024 Category: Cancer & Oncology Source Type: research

Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer
ConclusionFirst-line ICIs plus chemotherapy should be applied in clinical practice. If patients did not use ICIs plus chemotherapy in first-line therapy, the use of ICIs in the second line or subsequent lines of treatment could prolong PFS2. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 10, 2024 Category: Cancer & Oncology Source Type: research

The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review
AbstractIndeed, tumors are a significant health concern worldwide, and understanding the underlying mechanisms of tumor development is crucial for effective prevention and treatment. Epigenetics, which refers to changes in gene expression that are not caused by alterations in the DNA sequence itself, plays a critical role in the entire process of tumor development. It goes without saying that the effect of methylation on tumors is a significant aspect of epigenetics. Among the methylation modifications, DNA methylation is an important part, which plays a regulatory role in tumor-related genes. Ten-eleven translocation 2 (T...
Source: Clinical and Translational Oncology - April 10, 2024 Category: Cancer & Oncology Source Type: research